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Abstract
Intriduction: The reported prevalence of chronic autoimmune thyroiditis associated with differentiated thyroid cancer (DTC) is hetero-
geneous. The aim of this study was to evaluate some epidemiological, clinical, sonographical and histological features of operated thyroid 
nodules with background diffuse autoimmune thyroiditis.
Material and methods: The study included 411 cases with Hashimoto’s thyroiditis (HT), of which 118 presented thyroid nodular disease 
(TND). Thyroidectomy was performed in 76 cases. Of these patients, 24 presented histologically confirmed DTC and 52 benign lesions. 
DTC types were as follows: papillary thyroid cancer (PTC) (n = 6), follicular variant of PTC (FVPTC) (n = 6), papillary microcarcinomas 
(n = 8), follicular thyroid carcinoma (n = 1) and the mixed form (classic PTC and FVPTC) (n = 3). The benign nodules were dominated 
by: follicular adenoma (48%), and colloid goitre (40.3%).
Results: The sonographic features with predictive risk for malignancy in cases with HT associated with TND were represented by: solid 
composition, hypoechogenicity and microcalcifications. The characters of margins, the nodular shape and the type of vascularity do not 
seem to be as useful for identification of malignant nodules in HT. Fine needle-aspiration biopsy (FNAB) showed in DTC cases different 
cytological smears: malignant (ten), indeterminate (eight), benign (two), and non-diagnostic (four). In the group of benign nodules, the 
indeterminate smears represented also a significant percentage (n = 12). 
Conclusions: The incidence of TND associated with HT was 28.7%. Among 76 operated cases, 31.5% presented DTC. The accuracy 
of FNAB in the preoperative diagnosis showed higher sensitivity (90.0%) and specificity (61.5%) compared to sonographic criteria. 
(Endokrynol Pol 2013; 64 (4): 255–262)
Key words: Hashimoto's thyroiditis, thyroid nodule, thyroid cancer
Streszczenie
Wstęp: Podawane w literaturze dane na temat rozpowszechnienia przewlekłego autoimmunologicznego zapalenia tarczycy związanego 
ze zróżnicowanym rakiem tarczycy (DTC, differentiated thyroid cancer) cechuje duża rozpiętość. Celem badania była ocena wybranych cech 
epidemiologicznych, klinicznych, ultrasonograficznych i histopatologicznych operowanych guzków tarczycy u pacjentów z rozlanym 
autoimmunologicznym zapaleniem tarczycy.
Materiał i metody: Do badania włączono 411 przypadków choroby Hashimoto (HT, Hashimoto thyroiditis), z czego 118 pacjentów zgłosiło 
się do lekarza z powodu choroby guzkowej tarczycy (TND, thyroid nodular disease). Tyroidektomię wykonano u 76 pacjentów, przy czym 
u 24 pacjentów badanie histopatologiczne wykazało DTC, a u pozostałych 52 — zmiany łagodne. Postacie DTC były następujące: rak 
brodawkowaty tarczycy (PTC, papillary thyroid cancer) (n = 6), wariant pęcherzykowy PTC (FVPTC, follicular variant of papillary thyroid 
cancer) (n = 6), mikroraki brodawkowate (n = 8), rak pęcherzykowy tarczycy (n = 1) i postać mieszana (klasyczny PTC i FVPTC) (n = 3). 
Większość guzków łagodnych stanowiły gruczolaki pęcherzykowe (48%) i wole koloidalne (40,3%).
Wyniki: Cechy ultrasonograficzne związane z ryzykiem rozpoznania nowotworu złośliwego w przypadkach HT związanej z TND obej-
mowały: litą strukturę, hipoechogenność i mikrozwapnienia. Charakter brzegów, kształt guzkowaty i typ unaczynienia nie wydają się 
użytecznymi parametrami w identyfikacji guzków złośliwych w HT. Biopsja aspiracyjna cienkoigłowa (BAC) wykazała w przypadkach 
DTC różne obrazy cytologiczne: złośliwy (10), nieokreślony (8), łagodny (2) i niediagnostyczny (4). W grupie z guzkami łagodnymi nie-
określony obraz cytologiczny stanowił duży procent wyników (n = 12).
Wnioski: Częstość występowania TND związanego z HT wyniosła 28,7%. Wśród 76 operowanych pacjentów DTC stwierdzono w 31,5% 
przypadków. Dokładność BAC w rozpoznaniu przedoperacyjnym cechowała się większą czułością (90,0%) i swoistością (61,5%) w po-
równaniu z kryteriami ultrasonograficznymi. (Endokrynol Pol 2013; 64 (4): 255–262)
Słowa kluczowe: choroba Hashimoto, guzek tarczycy, rak tarczycy
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Introduction
Dailey and Lindsay were the first to report in 1955 the 
association between Hashimoto’s thyroiditis (HT) and 
differentiated thyroid cancer (DTC) [1]. Since then, 
many other studies have confirmed this coexistence 
with variable incidence rates. Several reports have es-
tablished a prevalence of 11-36% of patients with coex-
istent HT and papillary thyroid carcinoma (PTC) [2–5]. 
The majority of these studies are based on retrospective 
analysis of surgical series. HT and DTC (mainly PTC) 
share some epidemiological features, like the relation-
ship with dietary iodine and radiation exposure. Both 
diseases affect mainly women, showing also certain 
common molecular features. RET/PTC combinations are 
common in PTC, being associated with the characteristic 
nuclear changes [6]. Others have shown an increased 
PI3K/Akt expression in both diseases [7]. Unger et al. 
found expression of p63 in Hashimoto patients with 
PTC [8, 9]. 
Although the association between HT and DTC has 
been frequently reported, it is unknown whether these 
thyroid disorders share a common origin and whether 
the presence of HT affects the biologic behaviour of 
PTC.
The aim of this study was to present some epide-
miological aspects regarding the prevalence of thyroid 
nodular disease (TND) in HT and to analyse the ultra-
sonographic (US) and cytological features of proven 
benign and malignant lesions, diagnosed in cases with 
background diffuse autoimmune thyroiditis.
Material and methods
The clinical material, represented by 411 cases of HT, 
issued from an iodine-replete area (the western plain 
of Romania), was evaluated retrospectively and pro-
spectively (January 2008–April 2012).
A total of 293 patients presented the diffuse form of 
the disease and 118 associated TND.
Informed consent forms were obtained from all 
patients. The study was approved by the local Ethics 
Committee. The study was performed in accord-
ance with the Helsinki Declaration and good clinical 
practice.
The inclusion criteria were: female and male sub-
jects, all age groups and confirmed HT (by immunologi-
cal investigations and thyroid US). In cases without de-
tectable antibodies (Abs), the diagnosis was established 
by US and fine needle aspiration biopsy (FNAB).
Serum samples were tested for TSH (reference 
values: 0.46-4.67 mIU/L) and free T4 (reference values: 
0.71-1.85 ng/dL), using ARCHITECT i2000 SR (Abbot 
Diagnostics). 
Antithyroid antibodies (AT Abs) were measured 
by CMIA, using Abbot AxSYM System. The normal 
values were for TPO Abs < 12 IU/mL and for Tg Abs 
< 35 IU/mL.
Thyroid US was performed using a Picker sono-
graph equipped with a linear transducer of 7.5MHz 
and power Doppler capability. A nodule was defined 
as an intrathyroidal lesion of any size that was so-
nographically distinct from the surrounding thyroid 
parenchyma. 
The US analysis of nodules comprised the following 
characteristics:
 — the measurement of the largest nodular diameter 
(mm);
 — the composition of nodule (solid, cystic);
 — the nodular echogenicity (isoechoic, hypoechoic, 
hyperechoic);
 — the halo sign (present, absent);
 — the characters of nodular margins (well-defined, 
ill-defined); 
 — microcalcifications (absent, present);
 — the nodular vascularity was quantified by Dop-
pler US. Three types of nodule vascularity were 
described: type 1 —  absence of flow signals; type 
2 — increased perinodular vascularisation, and 
type 3 — increased perinodular and intranodular 
vascularisation.
FNAB was carried out in nodules ≥ 10 mm and in 
those presenting more than two suspicious US features. 
Aspirated findings were classified into one of four clas-
sical cytological categories: non-diagnostic, benign, 
indeterminate, and malignant. 
Surgery was performed in 76 cases because of dif-
ferent reasons: family history of thyroid carcinoma 
(two cases), autonomous adenoma (two), cytological 
diagnosis (45), compressive symptoms and signs (19) 
and patients’ desire (eight) (Fig. 1).
The performed surgery consisted of: total thyroidec-
tomy ± neck dissection, total lobectomy and isthmusec-
Figure 1. Indications for surgery (76 cases)
Rycina 1. Wskazania do zabiegu (76 przypadków)
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tomy or unilateral subtotal thyroidectomy, depending 
on the case. For malignant cases we used radioactive 
iodine remnant ablation (using 100–150 mCI 131I).
Non-operated patients were treated with thyroxine 
when hypothyroid and re-evaluated US two times per 
year. 
Statistical analysis
Continuous data was expressed as means with stand-
ard deviations (SD). Categorical data was expressed 
as frequency and percentage. Baseline characteristics 
were compared using the Wilcoxon Rank Sum text and 
Fisher’s exact test as appropriate. 
The sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) 
of preoperative diagnosis using FNAB and US char-
acteristics were calculated, with the final diagnosis 
established through morphopathological analysis of 
surgical specimens. 
The statistical analyses were performed using SPSS 
version 14 for Windows (SPSS Inc, Chicago, IL, USA).
Results
The epidemiological, functional and immunological 
data of studied cases are depicted in Table I.
Some aspects of operated patients, classified after 
morphopathological diagnosis, are represented in 
Table II.
DTC cases were represented by: classical PTC 
(n = 6), follicular variant of PTC (FVPTC) (n = 6), 
papillary microcarcinoma (five cases — single carci-
noma, two cases — multicentric carcinoma and one 
case — follicular variant), follicular thyroid carcinoma 
Table II. Epidemiological, clinical and immunological data of operated cases with HT and TND
Tabela II. Dane epidemiologiczne, kliniczne i immunologiczne u operowanych pacjentów z HT i TND
Character 
(no. of cases)
Malignant nodules 
(n = 24)
Benign nodules 
(n = 52)
p
Age (mean ± SD) (years) 53.2 ± 13.4 49.8 ± 13.1 0.44†
M/F 1/23 4/48 NS‡
Incidentaloma 4 9 NS‡
Compressive symptoms and signs 4 18 0.17‡
Thyroid functionality Euthyroidism — 21
Hypothyroidism — 3
Euthyroidism — 44
Hyperthyroidism — 2
Hypothyroidism — 6
NS‡
Polinodular goitre 0 2 NS‡
†Student´s unpaired t test; ‡Fisher´s exact test
Table I. Epidemiological, functional and immunological data of HT cases with and without TND
Tabela I. Dane epidemiologiczne, czynnościowe i immunologiczne u pacjentów z HT z towarzyszącą TND i bez towarzyszącej 
TND
Parameter HT with TND
(n = 118)
Diffuse HT
(n = 293)
p
Mean age (yrs) ± SD 52.3 ± 16.3 47.65 ± 15.32 0.006†
Male (M)/Female (F) 5/113 21/272 NS‡
TSH [mIU/L]
(mean ± SD)
13.30 ± 7.47 16.87 ± 11.22 0.001†
fT4 [ng/dL]
(mean ± SD)
0.99 ± 0.41 1.06 ± 0.34 NS†
Positive anti TPO Abs (significant 
titers)
99/118 215/283 0.08‡
Positive anti Tg Abs
(significant titers)
60/118 151/270 0.37‡
†Student´s unpaired t test; ‡Fisher´s exact test
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(n = 1), and mixed form (classic PTC associated with 
FVPTC) (n = 3).
Preoperative FNAB of DTC cases revealed the fol-
lowing cytological diagnosis: malignant in ten cases, 
benign in two cases, indeterminate in eight patients, 
and non-diagnostic in four patients.
Histopathological diagnosis of benign lesions was 
represented by: follicular adenoma (n = 25), colloid 
goitre (n = 21), Hürthle cell adenoma (n = 2), follicu-
lar hyperplasia (n = 2), and nodular HT (n = 2). The 
cytological diagnosis of these cases was as follows: 
malignant in three patients, benign in 24 subjects, 
indeterminate in 12 patients, and non-diagnostic in 
two cases.
The US characteristics of proven benign and ma-
lignant nodules with background HT are depicted in 
Table III.
The diagnostic accuracy of US characteristics for 
malignant nodules is depicted in Table IV and the risk 
factors for malignancy are presented in Table V.
The US parameters (solid composition, hypoechoic 
appearance, halo, microcalcifications, margins, vascu-
larity) of large malignant thyroid nodules (> 15 mm 
diameter) did not differ significantly from the smaller 
ones (< 14 mm diameter).
In 39 cases, the US features of benignity were cor-
roborated with cytological and morphopathological 
diagnoses (Table VI). Table VII shows the cytological and 
the morphopathological diagnoses of operated cases. 
The sensitivity, specificity, PPV and NPV of FNAB are 
shown in Table VIII.
Discussion
The association between TND and autoimmune thy-
roiditis is nowadays well-recognised.
In the present analysis, the prevalence of this coexist-
ence was 28.7%. Among 76 operated cases with HT and 
TND, there were diagnosed 68.4% benign nodules and 
31.5% DTC. Others have found a lower prevalence of 
Table III. US characteristics of proven malignant and benign thyroid nodules with background diffuse HT
Tabela III. Charakterystyka ultrasonograficzna potwierdzonych złośliwych i łagodnych guzków tarczycy u pacjentów z rozlaną HT
Character 
(no. of cases)
Malignant nodules 
(n = 24)
Benign nodules 
(n = 52)
p
Largest nodular diameter (mean ± SD) [mm] 24 ± 10 28 ± 14 0.21†
Composition
Predominantly solid
Predominantly cystic
22
2
31
21
0.006‡
Echogenicity
Isoechoic
Hypoechoic
Hyperechoic
5
19
0
21
18
13
0.001#
Halo
Absent or thick, irregular 
Thin, regular 
19
5
22
30
0.07‡
Margins
Well-defined
Ill-defined
11
13
35
17
0.08‡
Microcalcifications
Absent
Present
9
15
44
8
< 0.0001‡
Height/width ≥ 1 8 11 0.26‡
Vascularity pattern
1
2
3
8
8
8
16
21
15
0.83#
† Student´s unpaired t test; ‡ Fisher´s exact test; # Chi-square test
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HT and benign TND vs. HT and DTC (6.7% vs. 23.8%) 
[10–12]. 
Some investigators have shown that the incidence 
rate of HT is 2.77 times higher in cases with PTC than in 
those with benign thyroid disease. At the same time, in 
patients with DTC, the incidence rate of the association 
with HT is 1.99 times higher in those with PTC than in 
cases with other forms of thyroid carcinoma [2, 3]. HT 
seems to be a stronger predictor for PTC than other 
risk factors [13].
The reported prevalence of microcarcinomas in 
HT is 36.6% [12]. The association of HT with primary 
thyroid lymphoma has been noted [15, 16].
The heterogeneity of the coexistence of DTC and 
HT in different studies seems to be related to differ-
ent factors (individual differences in patient selection, 
indications for thyroidectomy, the level of pathological 
examination) [17–19].
In the present study, between diffuse HT and HT 
associated with TND, significant differences were ob-
served regarding mean age (higher in nodular cases) 
and TSH levels (more increased in the diffuse form) 
(Table I).
The clinical parameters did not significantly differ in 
proven benign and malignant nodules (Table II). Some 
investigators observed the same aspects [20]. The mor-
phopathological analysis showed in the DTC group dif-
ferent variants of PTC (classical form: six cases, follicular 
variant of PTC-FVPTC: six, papillary microcarcinomas: 
eight, follicular thyroid carcinoma-FTC: one patient and 
the mixed form-PTC and FVPTC: three cases). 
The literature also describes other types of malignant 
lesions such as medullary carcinomas and even ana-
plastic thyroid cancer [21]. Generally, the percentages 
of PTC exceed those of FTC and medullary carcinoma 
[20–22].
The cases with benign nodules presented the fol-
lowing diagnoses: follicular adenomas, colloid goitres, 
Hürthle cell adenomas, follicular hyperplasia, and 
nodular or focal Hashimoto’s thyroiditis, similar to 
other reported studies [20].
Analysing the US characteristics of proven ma-
lignant nodules vs. benign ones in HT, we remarked 
significant differences regarding the following features: 
composition (p = 0.006), echogenicity (p = 0.001), and 
the presence of microcalcifications (p < 0.0001). While 
most malignant nodules were solid, hypoechoic, with 
microcalcifications, the benign ones presented well-
defined margins (Table III).
The classical US characteristics of malignancy in 
a thyroid nodule are represented by: marked hypo-
echoic aspect, solid composition, absent halo, ill-defined 
margins, microcalcifications, predominantly central 
vascularity, and a certain shape (more tall than wide) 
[24–28]. 
The US characters of benignity are considered 
the following: the presence of a cystic component, 
a sponge-like structure, hyperechogenicity, present halo 
(thin, regular), well-defined margins, and no central 
vascularity [29, 30].
Since 1990, several studies have analysed the re-
lation between specific US characteristics of thyroid 
nodules and malignancy [30, 31]. Most studies have 
remarked a limitation of specificity and sensitivity of 
Table IV. Diagnostic accuracy of US features in malignant nodules with background HT 
Tabela IV. Dokładność diagnostyczna cech ultrasonograficznych guzków złośliwych u pacjentów z HT
Parameter Sensitivity (%) Specificity (%) Positive predictive 
value (%)
Negative predictive 
value (%)
Accuracy (%)
Solid composition 22/24 (91.7) 21/52 (40.4) 22/53 (41.5) 21/23 (91.3) 43/76 (56.6) 
Hypoechoic appearance 19/24 (79.2) 34/52 (65.4) 19/37 (51.4) 34/39 (87.2) 53/76 (69.8) 
Microcalcifications 15/24 (62.5) 44/52 (84.7) 15/23 (65.3) 44/53 (83.1) 59/76 (77.7) 
Absent or thick, irregular halo 19/24 (79.2) 24/52 (46.2) 19/47 (40.5) 24/29 (82.8) 43/76 (56.6) 
Poorly defined margins 17/24 (70.9) 40/52 (77) 17/29 (58.7) 40/47 (85.1) 57/76 (75) 
Intranodular vascularity 8/24 (33.4) 37/52 (71.2) 8/23 (34.8) 37/53 (70) 45/76 (59.3) 
Table V. Risk factors for malignancy of thyroid nodules 
in HT
Tabela V. Czynniki ryzyka złośliwego charakteru guzków 
tarczycy u pacjentów z HT
Risk factor Relative risk  
(95 % CI)
Predominantly solid composition 1.5 (1.1–1.9)
Hypoechoic 2.2 (1.4–3.5)
Absent halo 1.2 (0.7–2.0)
Ill defined margins 1.6 (0.9–2.8)
Microcalcifications 4.0 (1.9–8.2)
Height/width ≥ 1 1.5 (0.7–3.4)
Size > 15 mm 0.7 (0.4–1.0)
Intranodular vascularity 1.1 (0.5–2.3)
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specific US features in the prediction of malignancy. It 
is considered that no individual US feature has high 
sensitivity and a good specificity for the detection of 
malignancy.
Table VI. Corroboration of US features, cytological and morphopathological pictures in 39 benign nodules with HT 
Tabela VI. Potwierdzenie cech ultrasonograficznych, obrazu cytologicznego i obrazu histopatologicznego w 39 łagodnych 
guzkach u pacjentów z HT
US pattern No of cases Cytological diagnosis Morphopathological diagnosis
Sponge-like 6 Benign — 2
Indeterminate — 4
Colloid goitre — 2
Follicular adenoma — 4
Cyst with colloid clot 20 Benign — 8
Indeterminate — 10
Malignant — 2
Colloid goitre — 8
Follicular adenoma — 9, Hürthle cell adenoma — 1
HT — 2
‘White knight’ 13 Benign — 6
Indeterminate — 5
Non-diagnostic — 2
Colloid goitre — 6
Follicular adenoma — 7
Table VII. Correlation of cytological and histopathological diagnoses in malignant and benign nodules with HT background
Tabela VII. Korelacja między rozpoznaniem cytologicznym i rozpoznaniem histopatologicznym w przypadku guzków 
złośliwych i łagodnych u pacjentów z HT
Cytology
Morphopathology
CG HT FA HCA PTC FVPTC FTC Mixed PTC PmC F Hyper
Benign 
(n = 26) 
20 2 2 2 
Indeterminate 
(n = 20) 
11 1 5 1 2 
Malignant 
(n = 13) 
2 1 6 3 1 
Non-diagnostic 
(n = 6) 
2 1 3 
CG — colloid goitre; HT — Hashimoto’s thyroiditis; FA — follicular adenoma; HCA — Hürthle cell adenoma; PTC — papillary thyroid cancer; FVPTC — follicular variant 
of PTC; FTC — follicular thyroid carcinoma; PmC — papillary microcarcinoma; F Hyper — follicular hyperplasia
Table VIII. Accuracy of FNAB in the preoperative diagnosis 
of thyroid nodules in patients with background HT (65 cases)
Tabela VIII. Dokładność BAC w rozpoznaniu przedoperacyjnym 
guzków tarczycy u pacjentów z HT (65 przypadków)
Postoperative histopathological diagnosis
Preoperative FNAB 
diagnosis
Malignant nodules  
(n = 20)
Benign nodules  
(n = 41)
Malignant (13) 10 3
Benign (26) 2 24
Non-diagnostic (6) 4 2
Indeterminate (20) 8 12
Sensitivity 90.0%; Specificity 61.5%; PPV 54.5%; NPV 92.3%; Accuracy 64.6%.
It is difficult to establish if the US characteristics of 
malignancy are the same in the general population and 
in cases with background HT. Given the hypoecho-
genicity, specific echostructure and increased vascu-
larity of HT, it seems reasonable to question whether 
existing guidelines are appropriate for this particular 
patient population [32]. No individual US parameter 
is suitable for preoperative diagnosis of malignancy in 
HT. Ultrasonographically, HT and HT associated with 
PTC may present very similar pictures [20, 33, 34]. The 
accuracy of US analysis of thyroid cancer in the general 
population does not seem totally different from that 
performed in cases with DTC with background HT 
(see Table VIII). 
Anderson et al. observed that in malignant nodules 
within diffuse HT, all types of calcifications were more 
prevalent (microcalcifications, macrocalcifications and 
peripheral eggshell calcifications). At the same time, 
they decided that margin characteristics and vascular-
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ity did not seem to be as useful in patients with HT 
background [32].
Liu ascertained that the presence of poorly defined 
margins was the only US significant parameter for the 
differentiation of benign nodules vs. malignant in HT 
[20]. 
The analysis of US features of malignant nodules 
in HT with respect to size did not reveal significantly 
different aspects between large nodules (≥ 15 mm) and 
small nodules (< 14 mm). This aspect, observed also by 
others [35, 36], enlarges the opportunity for cytological 
examinations for small thyroid nodules. 
Some investigators [37, 38] have preferred to 
consider a more pattern-oriented US approach as an 
alternative to the analysis of individual features. More 
nodular patterns with or without indication for FNAB 
were depicted. They consider biopsy mandatory in 
the following four patterns: hypoechoic nodule with 
microcalcifications; hypoechoic nodule with coarse cal-
cifications; well-marginated, solid, ovoid nodules with 
a thin hypoechoic halo; and solid mass with refractive 
shadowing from the edges.
The same authors found that the use of a pattern 
approach to thyroid nodules is highly sensitive and spe-
cific for benignity. Four patterns invariably benign were 
identified (histological diagnosis). The patterns with no 
indication for FNAB are represented by the following: 
1 — spongiform nodule (‘puff pastry’); 2 — cyst with 
colloid clot; 3 —’ giraffe’, and 4 — hyperechoic nodule 
(‘white knight’) [37, 38].
We detected 39 cases with a ‘benign’ US pattern 
(spongiform: six cases; cyst with colloid clot: 20, and 
‘white knight’: 13 cases). FNAB results were dominated 
by indeterminate and benign smears (19, 16 patients 
respectively). The histological analysis detected always 
benign nodules.
FNAB showed in DTC cases different cytological 
smears: malignant (ten), indeterminate (eight), benign 
(two), and non-diagnostic (four). In the group of pa-
tients with benign nodules, the indeterminate smears 
represented also a significant percentage (29.2%) (Table 
VII). Some investigators report that 25–50% of cyto-
logical indeterminate nodules prove to be malignant 
upon final morphopathological diagnosis [37]. The 
American Thyroid Association and the European 
Thyroid Association recommend partial or near-total 
thyroidectomy for patients with indeterminate nodular 
cytology [27, 40].
Recently, investigators have studied the potential of 
clinical, radiological, and molecular markers to predict 
cancer or benignity. The use of multivariate assessment 
demonstrated the benefits of an approach using several 
risk factors in conjunction with cytological findings.
The clinical variables considered able to predict ma-
lignancy are: age (< 18–25 yr), patient sex (male) and 
nodule size [28, 30, 41]. Others suggest no influence of 
nodule size on cancer risk.
The corroboration of cytological and morphopatho-
logical diagnoses in our cases (presented in Table VII) 
showed a low percentage of false-negative (n = 2) and 
false-positive cases (n = 3).
The accuracy of FNAB in the preoperative diagno-
sis of thyroid nodules in cases with background HT 
(presented in Table VIII) showed a sensitivity of 90.0% 
and a specificity of 61.5%, higher values than those of 
US criteria.
The significant occurrence of follicular lesions re-
sulted in an important percentage of indeterminate 
cytological smears. This aspect has also been observed 
in other studies [20, 42, 43].
Indeterminate smears may induce cytologic diag-
nostic errors in HT, as a result of overlapping cytologic 
features, particularly among: Hürthle cell neoplasm, 
follicular neoplasm, PTC, and others.
Conclusions
The diagnosis of TND with background diffuse HT 
imposes systematically thyroid US.
In the present study, the prevalence of TND associ-
ated with HT was 28.7%. Among the operated cases (76 
patients), 31.5% presented different forms of DTC and 
68.4% various benign lesions.
The US characteristics of benign and malignant 
nodules within diffuse HT seem to be generally similar 
to those described in the general population. The US 
features with predictive risk for malignancy in cases 
with HT associated with TND were represented by: 
solid composition, hypoechogenicity and microcalcifi-
cations. The characters of margins, the nodular shape 
and the type of vascularity do not seem to be as useful 
for identification of malignant nodules in HT.
While DTC cases were dominated by microcarci-
nomas, classical PTC and PTCFV, the benign nodules 
were mainly represented by follicular lesions (follicular 
adenoma, Hürthle cell adenoma and follicular hyper-
plasia). The important prevalence of follicular lesions 
with indeterminate smears explains the significant 
number of operated cases.
The accuracy of preoperative FNAB (sensitivity 
90.0%, specificity 61.5%, NPV 92.3%) was superior to 
that of US criteria.
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